Signal #144948 · SEC 8-K

$NTLA SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $NTLA filing catalyst

Why did $NTLA trigger an AI stock catalyst alert?

$NTLA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.5/10). Headline: Intellia Therapeutics Reports Q3 Net Loss Widening to $127.5M as Revenue Declines. Key points: - Collaboration revenue decreased to $7.2M from $13.8M in Q3 prior year, driven by lower Regeneron revenue. - Net loss widened to $127.5M compared to $101.3M in Q3 2025. - Pipeline updates include MAGNITUDE-2 trial enrollment completion and lonvo-z PDUFA target date of March 10, 2027.

How did $NTLA stock react after the SEC filing?

After the SEC 8-K for $NTLA, observed market reaction: T0 price $12.31. Past moves do not guarantee future results.

Where can I get real-time $NTLA SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $NTLA via Telegram and the VIP Web Terminal from €10/month.

$NTLA

$NTLA – Intellia Therapeutics Reports Q3 Net Loss Widening to $127.5M as Revenue Declines

Intellia Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $NTLA

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-2.5 / 10)

Collaboration revenue decreased to $7.2M from $13.8M in Q3 prior year, driven by lower Regeneron revenue.
Net loss widened to $127.5M compared to $101.3M in Q3 2025.
Pipeline updates include MAGNITUDE-2 trial enrollment completion and lonvo-z PDUFA target date of March 10, 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →